Cargando…

The effect of unfractionated heparin, enoxaparin, and danaparoid on lupus anticoagulant testing: Can activated carbon eliminate false‐positive results?

BACKGROUND: Heparins and heparinoids interfere with functional clotting assays used for lupus anticoagulant (LAC) detection. However, current guidelines for LAC testing do not provide clear guidance on this matter. OBJECTIVES: We aimed to assess to effect of unfractionated heparin (UFH), enoxaparin,...

Descripción completa

Detalles Bibliográficos
Autores principales:	De Kesel, Pieter M.M., Devreese, Katrien M.J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2019
Materias:	Original Articles: Thrombosis
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6971310/ https://www.ncbi.nlm.nih.gov/pubmed/31989098 http://dx.doi.org/10.1002/rth2.12264

Ejemplares similares

Differential Neutralization of Unfractionated Heparin and Enoxaparin by Andexanet Alfa
por: Lewis, Joseph, et al.
Publicado: (2022)

Direct Oral Anticoagulant removal by a DOAC filter: Impact on lupus anticoagulant testing – Evaluation on spiked and patient samples
por: Linskens, Eleni A., et al.
Publicado: (2022)

Outcomes of thromboprophylaxis with enoxaparin vs. unfractionated heparin in medical inpatients
por: McGarry, Lisa J, et al.
Publicado: (2006)

Effectiveness, safety, and costs of thromboprophylaxis with enoxaparin or unfractionated heparin in inpatients with obesity
por: Amin, Alpesh, et al.
Publicado: (2023)

Cost-utility of enoxaparin compared with unfractionated heparin in unstable coronary artery disease
por: Nicholson, Tricia, et al.
Publicado: (2001)

Enoxaparin versus Unfractionated Heparin for the Perioperative Anticoagulant Therapy in Patients with Mechanical Prosthetic Heart Valve Undergoing Non-Cardiac Surgery
por: Iliuta, Luminita, et al.
Publicado: (2022)

Anti‐β2‐glycoprotein I and anti‐prothrombin antibodies cause lupus anticoagulant through different mechanisms of action
por: Noordermeer, Tessa, et al.
Publicado: (2021)

Assay-Based Differentiation in the Neutralization Profile of Unfractionated Heparin, Enoxaparin, and Fondaparinux by Andexanet Alfa
por: Siddiqui, Fakiha, et al.
Publicado: (2020)

Cost-effectiveness analysis of alternative anticoagulation in suspected heparin-induced thrombocytopenia
por: Tuleja, Aleksandra, et al.
Publicado: (2022)

Enoxaparin is associated with lower rates of mortality than unfractionated Heparin in hospitalized COVID-19 patients
por: Pawlowski, Colin, et al.
Publicado: (2021)

Enoxaparin may be associated with lower rates of mortality than unfractionated heparin in neurocritical and surgical patients
por: Samuel, Sophie, et al.
Publicado: (2023)

The economic impact of enoxaparin versus unfractionated heparin for prevention of venous thromboembolism in acute ischemic stroke patients
por: Pineo, Graham F, et al.
Publicado: (2012)

Unfractionated Heparin with Sequential Enoxaparin in Patients with Complex Coronary Artery Lesions during Percutaneous Coronary Intervention
por: Li, Zhi-Zhong, et al.
Publicado: (2018)

Comparison of the Effect of Unfractionated Heparin and Enoxaparin Sodium at Different Doses on the Course of COVID-19-Associated Coagulopathy
por: Oliynyk, Oleksandr, et al.
Publicado: (2021)

Usefulness of Danaparoid sodium in patients with Heparin-induced thrombocytopenia after cardiac surgery
por: Foroughinia, Farzaneh, et al.
Publicado: (2015)

Efficacy and safety of enoxaparin versus unfractionated heparin during percutaneous coronary intervention: systematic review and meta-analysis
por: Silvain, Johanne, et al.
Publicado: (2012)

Adverse Outcomes of Anticoagulant Use among Hospitalized Patients with Chronic Kidney Disease: A Comparison of the Rates of Major Bleeding Events between Unfractionated Heparin and Enoxaparin
por: Saheb Sharif-Askari, Fatemeh, et al.
Publicado: (2014)

Switching from vitamin K antagonists to direct oral anticoagulants: Treatment satisfaction and patient concerns
por: Toorop, Myrthe M. A., et al.
Publicado: (2020)

Lupus anticoagulant test persistence over time and its associations with future thrombotic events
por: Colling, Meaghan E., et al.
Publicado: (2022)

Defective fibrin deposition and thrombus stability in Bambi (−/−) mice are mediated by elevated anticoagulant function
por: Crawley, James T. B., et al.
Publicado: (2019)

Impact of different anticoagulation management strategies on outcomes in atrial fibrillation: Dutch and Belgian results from the GARFIELD‐AF registry
por: Seelig, Jaap, et al.
Publicado: (2020)

The impact of repeated freeze‐thaw cycles on antiphospholipid antibody titer
por: Maelegheer, Karel, et al.
Publicado: (2018)

Outcomes in patients undergoing periprocedural interruption of warfarin or direct oral anticoagulants
por: Lee, Jeffrey, et al.
Publicado: (2022)

Unfractionated heparin and enoxaparin reduce high-stretch ventilation augmented lung injury: a prospective, controlled animal experiment
por: Li, Li-Fu, et al.
Publicado: (2009)

Danaparoid sodium-based anticoagulation therapy for portal vein thrombosis in cirrhosis patients
por: Hayashi, Takehiro, et al.
Publicado: (2019)

Ruling out lupus anticoagulants with mixing test–specific cutoff assessment and the index of circulating anticoagulant
por: Kumano, Osamu, et al.
Publicado: (2019)

DOAC‐Stop in lupus anticoagulant testing: Direct oral anticoagulant interference removed in most samples
por: Baker, Steven Andrew, et al.
Publicado: (2021)

Sex‐specific differences in clot resolution 3 weeks after acute pulmonary embolism managed with anticoagulants—A substudy of the EINSTEIN‐PE study
por: Wiegers, Hanke M. G., et al.
Publicado: (2021)

Novel inhibitor ZED3197 as potential drug candidate in anticoagulation targeting coagulation FXIIIa (F13a)
por: Pasternack, Ralf, et al.
Publicado: (2019)

Time in the Therapeutic Range for Assessing Anticoagulation Quality in Patients Receiving Continuous Unfractionated Heparin
por: Ting, Clara, et al.
Publicado: (2018)

Comparison between nafamostat mesilate and unfractionated heparin as anticoagulant during continuous renal replacement therapy
por: Makino, S, et al.
Publicado: (2015)

Extended anticoagulation treatment for cancer‐associated thrombosis—Rates of recurrence and bleeding beyond 6 months: A systematic review
por: Moik, Florian, et al.
Publicado: (2021)

Unfractionated and low molecular weight heparin
por: Lima, Marcelo, et al.
Publicado: (2014)

Standard dosing of enoxaparin versus unfractionated heparin in critically ill patient with COVID-19: a multicenter propensity-score matched study
por: Al Sulaiman, Khalid, et al.
Publicado: (2022)

Achieving higher efficacy without compromising safety with factor XI inhibitors versus low molecular weight heparin for the prevention of venous thromboembolism in major orthopedic surgery—Systematic review and meta‐analysis
por: Presume, João, et al.
Publicado: (2022)

A comparison of enoxaparin with unfractionated heparins in patients with coronary heart disease in an emergency department in rural South Indian tertiary care teaching hospital
por: Ahmad, Akram, et al.
Publicado: (2015)

Prevention of arterial and venous thrombotic events in symptomatic peripheral arterial disease patients after lower extremity revascularization in the VOYAGER PAD trial: Dual anticoagulant/antiplatelet regimen vs antiplatelet therapy alone
por: Berkowitz, Scott D., et al.
Publicado: (2022)

Unfractionated heparin and mechanical thromboprophylaxis in hip arthroplasty
por: Garcia, Flávio Luís, et al.
Publicado: (2015)

Low-Dose Unfractionated Heparin with Sequential Enoxaparin in Patients with Diabetes Mellitus and Complex Coronary Artery Disease during Elective Percutaneous Coronary Intervention
por: Huang, Ji, et al.
Publicado: (2018)

Lupus anticoagulant mixing tests for multiple reagents are more sensitive if interpreted with a mixing test‐specific cut‐off than index of circulating anticoagulant
por: Kumano, Osamu, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_8oeebiqg1flh1gnvk5doplesp6